Open access peer-reviewed Edited Volume

Liver Cancer - Genesis, Progression and Metastasis

Mark Feitelson

Temple University

A pioneering researcher who partially elucidated the role of hepatitis B x in the pathogenesis of liver cancer and developing therapeutics from the gut microbiome against autoimmunity. Dr. Feitelson worked in a Nobel group for 9 years. He is CSO of SFA Therapeutics and has 11 patents.


Alla Arzumanyan

Temple University

A highly innovative researcher who is developing a safe, oral treatment for psoriasis, and by extension, other autoimmune diseases. Dr. Arzumanyan is a Research Associate Professor at Temple University and a Chief Development Officer for SFA Therapeutics.


Risk Factors Hepatitis B Hepatitis C NASH Gut Microbiome Dysbiosis Tumor Progression Cancer Stem Cells EMT Metastasis Current Therapies Future Therapies Resistance to Therapies

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Hepatocellular carcinoma (HCC) is among the most prevalent tumor types worldwide. Diagnosis is late because early HCC is mostly asymptomatic. The mortality rate is high even with current treatments. HCC can develop from multiple etiologies (e.g., hepatitis B and C as well as NASH), but the pathogenesis of this tumor type is poorly understood, as are the mechanisms of disease that are shared among its’ different etiologies.

This book will provide chapters that will attempt to identify common denominators of HCC pathogenesis at the molecular, cellular, and immunologic levels prior to tumor development and during tumor progression. This will define critical targets for new prognostic assays and therapeutic approaches that would be valuable prior to and after a cancer diagnosis.

Publishing process

Book initiated and editor appointed

Date completed: February 24th 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: June 25th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: September 13th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: November 12th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Mark Feitelson

Temple University

Mark Feitelson received his Ph.D. in Microbiology and Immunology in 1979 from UCLA. He began his work with hepatitis B at Stanford University, and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). He has since worked on the pathogenesis of hepatitis B. In 1991, Dr. Feitelson moved to Thomas Jefferson University where he became Professor of Pathology and Cell Biology. He also was director of a Molecular Diagnostics Lab in Microbiology. In 2007, Dr. Feitelson went to Temple University as a Professor of Biology. His work has been supported by NIH, industry and foundations, has more than 150 publications, and 180 abstracts. He is also CSO of SFA Therapeutics. He has 11 patents, has mentored over 130 students.

View profile

Book chapters authored 1

Books edited 0

Introducing your Author Service Manager

Ms. Tea Jurcic

Ask a question

Book will be abstracted and indexed in